Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
01 Abril 2024 - 8:05AM
Business Wire
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage
biotechnology company committed to identifying and accelerating the
development of life-transforming therapies for patients with severe
and rare diseases, today announced that data from a systematic
literature review assessing the frequency of fetal and neonatal
alloimmune thrombocytopenia (FNAIT) risk among pregnant mothers
will be presented at the Academy of Managed Care Pharmacy (AMCP)
2024 Annual Meeting in New Orleans from April 15th to 18th.
Rallybio is developing RLYB212, a novel human monoclonal
anti-HPA-1a antibody designed to prevent alloimmunization in
at-risk pregnant mothers, thereby eliminating the risk of FNAIT and
its potentially devastating consequences in fetuses and
newborns.
Details of the poster presentation are as follows:
- Title: Fetal and Neonatal Alloimmune Thrombocytopenia: A
Systematic Literature Review and Meta-analysis of Adverse
Pregnancy-Related Outcomes to Support the Development of a Novel
Prophylactic Therapeutic
- Presenting Author: Andrea V. Margulis, RTI Health
Solutions
- Poster Number: P1
- Poster Session Date and Time: April 17, 2024, 1:00 -
2:30 p.m. CDT (2:00 - 3:30 p.m. EDT)
Additional information about the AMCP 2024 Annual Meeting is
available at: https://amcpannual.org/
About FNAIT
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a
potentially life-threatening rare disease that can cause
uncontrolled bleeding in fetuses and newborns. FNAIT can arise
during pregnancy due to an immune incompatibility between an
expectant mother and her fetus in a specific platelet antigen
called human platelet antigen 1, or HPA-1.
There are two predominant forms of HPA-1, known as HPA-1a and
HPA-1b, which are expressed on the surface of platelets.
Individuals who are homozygous for HPA-1b, meaning that they have
two copies of the HPA-1b allele and no copies of the HPA-1a allele,
are also known as HPA-1a negative. Upon exposure to the HPA-1a
antigen, these individuals can develop antibodies to that antigen
in a process known as alloimmunization. In HPA-1a negative
expectant mothers bearing a HPA-1a positive fetus, alloimmunization
can occur upon mixing of fetal blood with maternal blood. When
alloimmunization occurs in an expectant mother, the anti-HPA-1a
antibodies that develop in the mother can cross the placenta and
destroy platelets in the fetus. The destruction of platelets in the
fetus can result in severely low platelet counts, or
thrombocytopenia, and potentially lead to devastating consequences
including miscarriage, stillbirth, death of the newborn, or severe
lifelong neurological disability in those babies who survive. There
is currently no approved therapy for the prevention or prenatal
treatment of FNAIT.
About Rallybio
Rallybio (Nasdaq: RLYB) is a clinical-stage biotechnology
company with a mission to develop and commercialize
life-transforming therapies for patients with severe and rare
diseases. Rallybio has built a broad pipeline of promising product
candidates aimed at addressing diseases with unmet medical need in
areas of maternal fetal health, complement dysregulation,
hematology, and metabolic disorders. The Company has two clinical
stage programs: RLYB212, an anti-HPA-1a antibody for the prevention
of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and
RLYB116, an inhibitor of complement component 5 (C5), with the
potential to treat several diseases of complement dysregulation, as
well as additional programs in preclinical development. Rallybio is
headquartered in New Haven, Connecticut. For more information,
please visit www.rallybio.com and follow us on LinkedIn and
Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on our management’s beliefs and assumptions and on currently
available information. All statements, other than statements of
historical facts contained in this press release are
forward-looking statements. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements
concerning whether a prophylactic treatment for FNAIT can be
successfully developed, and whether RLYB212 will prevent
alloimmunization in at-risk pregnant mothers and eliminate the risk
of FNAIT. The forward-looking statements in this press release are
only predictions and are based largely on management’s current
expectations and projections about future events and financial
trends that management believes may affect Rallybio’s business,
financial condition, and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks,
uncertainties and assumptions, including, but not limited to, our
ability to successfully initiate and conduct our planned clinical
studies, and complete such clinical studies and obtain results on
our expected timelines, or at all, whether our cash resources will
be sufficient to fund our operating expenses and capital
expenditure requirements and whether we will be successful raising
additional capital, our ability to enter into strategic
partnerships or other arrangements, competition from other
biotechnology and pharmaceutical companies, and those risks and
uncertainties described in Rallybio’s filings with the U.S.
Securities and Exchange Commission (SEC), including Rallybio’s
Annual Report on Form 10-K for the period ended December 31, 2023,
and subsequent filings with the SEC. The events and circumstances
reflected in our forward-looking statements may not be achieved or
occur and actual future results, levels of activity, performance
and events and circumstances could differ materially from those
projected in the forward-looking statements. Except as required by
applicable law, we are not obligated to publicly update or revise
any forward-looking statements contained in this press release,
whether as a result of any new information, future events, changed
circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240329464694/en/
Investor Ami Bavishi Head of Investor Relations and
Corporate Communications (475) 47-RALLY (Ext. 282)
abavishi@rallybio.com Hannah Deresiewicz Stern Investor Relations,
Inc. (212) 362-1200 hannah.deresiewicz@sternir.com Media
Victoria Reynolds Mission North (760) 579-2134
rallybio@missionnorth.com
Rallybio (NASDAQ:RLYB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Rallybio (NASDAQ:RLYB)
Gráfica de Acción Histórica
De May 2023 a May 2024